The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half
of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during
hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of
intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies
have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in
blood sugar when infusing native GLP-1.